Therapeutic drugs used in preclinical and clinical trials for the treatment of MPNSTs currently include mTOR inhibitors and its derivatives (such as everolimus and temsirolimus), with varied response on tumor growth inhibition when combined with other candidate drugs.14, 15, 16 The MEK inhibitor PD0325901 was reported to reduce tumor growth and prolong survival rate, but could not induce apoptosis in tumor cells,17 whereas tyrosine kinase inhibitors such as imatinib, sorafenib, and pazopanib, and cell division interfering agents and HSP90 inhibitors are also under investigation. This evidence concerns the gene MAP2K7 and neoplasm.